Synaptic Pharmaceutical Corporation

Other

Merck + Co., Inc.

Bharat Lagu

Dhanapalan Nagarathnam

Charles Gluchowski

Wai C Wong

Mohammad R Marzabadi

T G Murali Dhar

Dake Tian

Mark G Bock

Michael A Patane

Ben E Evans

George Chiu

Yoon T Jeon

Kamlesh P Vyas

Kanyin E Zhang

Hanumath P Kari

Shou Wu Miao

Donghui Cui

Michael Dunn

Margaret R Davis

Stewart Alwyn Noble

John M Wetzel

Randall C Newton

John E DeLeon

Tg Murali Dhar

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

This invention is directed to dihydropyrimidines which are selective antagonists for human &agr; receptors. This invention is also related to uses of these compounds for relaxing lower urinary tract tissue, treating benign prostatic hyperplasia and for the treatment of any disease where the antagonism of the &agr; receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Dihydropyrimidines and uses thereof

This invention is directed to oxazolidinone compounds which are selective antagonists for human &agr; receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr; receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Oxazolidinones and uses thereof

This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human &agr; receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the &agr; receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Morpholinone and morpholine derivatives and uses thereof

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Alpha 1a adrenergic receptor antagonists

This invention is directed to dihydropyrimidines which are selective antagonists for human &agr;,receptors. This invention is also related to uses of these compounds for relaxing lower urinary tract tissue, treating benign prostatic hyperplasia and for the treatment of any disease where the antagonism of the &agr;,receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

This invention is directed to dihydropyrimidine compounds of the following formula:

This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human &agr;,receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the &agr;,receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

This invention is directed to oxazolidinone compounds which are selective antagonists for human .alpha..sub.1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the .alpha..sub.1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Oxazolidinones as .alpha..sub.1A receptor antagonists

Growing community of inventors

Maywood, NJ, United States of America

Bharat Lagu